Drug Trial Radar · NCT04886258
Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis
Last checked: Nov 19, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
115
Actual
Start
Sep 20, 2021
Primary completion
Dec 14, 2024
Study completion Dec 23, 2024
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a double-blinded, two-arm, phase 2a study to assess efficacy, safety and tolerability of DFV890 in participants with symptomatic knee osteoarthritis.
Conditions
- Symptomatic Knee Osteoarthritis
Interventions
DFV890Drug
DFV890 was administered orally twice per day, 10 mg during 2 weeks and 25 mg during the next 10 weeks.
PlaceboDrug
Matching Placebo was administered orally twice per day during 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain SubscaleTime frame: Baseline, Week 12
Locations
31 sites in 8 countries. Site status is shown where the registry gives one.
ARENSIA Explor Med Res Clinic
Phoenix, Arizona
TriWest Reserach Associates
El Cajon, California
Skylight Health Res Inc Color Spr
Colorado Springs, Colorado
IRIS Research and Development
Plantation, Florida
Conquest Research
Winter Park, Florida
Ctr for Adv Research and Education
Gainesville, Georgia
Northwestern University
Chicago, Illinois
Novartis Investigative Site
San Miguel de Tucumán, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
San Miguel, Tucumán Province, Argentina
Novartis Investigative Site
Nový Jičín, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Uherské Hradiště, Czechia
Novartis Investigative Site
Brno, Czech Republic, Czechia
Novartis Investigative Site
Bad Doberan, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Leipzig, Germany
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Miskolc, Hungary
Novartis Investigative Site
Veszprém, Hungary
Novartis Investigative Site
Kecskemét, Bács-Kiskun county, Hungary
Novartis Investigative Site
Bucharest, Romania
Novartis Investigative Site
Cluj-Napoca, Cluj, Romania
Novartis Investigative Site
Nové Mesto nad Váhom, Slovakia
Novartis Investigative Site
Piešťany, Slovakia
Novartis Investigative Site
A Coruña, Spain
Novartis Investigative Site
Seville, Spain
Novartis Investigative Site
Sabadell, Barcelona, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.